Team

  • David Ellam, Chief Financial Officer

    David is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry.

    READ MORE ↓

  • Helen Parris, Senior VP, Commercial and General Manager of Tetris Pharma Ltd

    Helen has over 20 years of scientific, commercial and government affairs experience across several international biopharmaceutical companies. Before joining Tetris Pharma, Helen served as General Manager of Northern Markets (UK, Netherlands and Nordics) at Albireo Pharma, Inc., which was acquired by Ipsen in March 2023 and where she played a key role in establishing and building the regional affiliate.

    READ MORE ↓

  • Manjit Rahelu, Ph.D., Chief Business Officer

    Manjit is an accomplished strategic deal maker, with a strong scientific background and over 25 years of technical, commercial and financial experience across large and mid-sized pharmaceutical and biotechnology companies.

    READ MORE ↓

  • Lindsey Foulkes, Ph.D. Chief Operating Officer

    Lindsey was appointed Chief Operations Officer of Arecor in 2021 and is responsible for the management of operations and business development. Lindsey has a background in senior positions at life sciences companies, having previously been Senior Director, Business Development- Small Molecules at Liminal Biosciences, and Head of Strategic Business Development at Cangene Corporation.

    READ MORE ↓

  • Christine Soden, Non-Executive Director

    Christine Soden is a Non-Executive Director of Elementis plc.

    READ MORE ↓

  • Jeremy Morgan, Non-Executive Director

    Jeremy Morgan completed a Senior Executive Programme in General Management from London Business School and holds a BSc (Hons) in Applied Biology from Coventry University.

    READ MORE ↓

  • Jim MacDonald-Clink, VP, Business Development

    Jim MacDonald-Clink joined Arecor in November 2019 as VP, Business Development. Jim has over 25 years’ experience in healthcare, having previously worked at Mundipharma, where he was responsible for Business Development and established the biosimilar platform and oncology strategy via acquisition and licensing agreements. He also held roles at Astellas Pharma and Fujisawa. His experience includes various roles in R&D, Medical and Commercial functions.

    READ MORE ↓

  • Susan Lowther, Chief Financial Officer and Executive Director/Company Secretary

    Susan Lowther was appointed Chief Financial Officer and Company Secretary at Arecor in 2019 and has significant financial leadership experience across a broad range of public and private life science companies.

    READ MORE ↓

  • Laura Ciccolini, Ph.D., Director of Business Development & Licensing

    Laura joined Arecor in 2018 as Director of Business Development. Coming from a background in Engineering, she has gained international experience across a number of business functions in the pharmaceutical, biotechnology and engineering/technology industries. She is multi-lingual and has built and trained successful teams, developed products and services, and managed complex programmes on a global scale, enabling expansion of businesses across markets.


    READ MORE ↓

  • Thomas R. Pieber, MD

    Dr. Thomas Pieber has served as a member of our Scientific Advisory Board since September 2017. He is a clinical specialist in endocrinology and diabetes mellitus, whose research is dedicated to the relationship of inflammation, energy homeostasis and human diseases. His group has developed a novel technique called open-flow microperfusion (OFM) which is used to explore energy metabolism in adipose and muscle tissue in diabetes.

    READ MORE ↓

  • Eda Cengiz, MD MHS FAAP

    Dr. Eda Cengiz has served as a member of our Scientific Advisory Board since September 2017. She is Professor of Pediatrics at the University of California, San Francisco and Director of the Cross-bay Pediatric Diabetes Program. For over 14 years, Dr Cengiz was a faculty member with Yale Diabetes Research Group and has conducted diabetes related clinical studies focusing on methods to accelerate insulin action, diabetes technology, and closed-loop systems. She was Director of Yale’s Insulin Pharmacokinetics and Pharmacodynamics (PK-PD) Research Study Center and one of the founding Investigators of the pediatric diabetes registry and type 1 diabetes exchange registry.

    READ MORE ↓

  • Bruce Buckingham, MD

    Dr. Bruce Buckingham has served as a member of our Scientific Advisory Board since September 2017. He is Professor of Paediatrics (Endocrinology) at the Lucile Salter Packard Children’s Hospital, Stanford University School of Medicine. Dr. Buckingham’s major interest is in type 1 diabetes mellitus, continuous glucose sensor, and the development of an artificial pancreas.

    READ MORE ↓

  • Sam Fazeli, Ph.D., Non-Executive Director

    Sam Fazeli has served as a member of the Arecor Board of Directors since September 2017 and brings over 25 years of experience of conducting equity research as a pharmaceutical analyst, working at firms including Nomura International and HSBC.

    READ MORE ↓

  • David Gerring, Chief Development Officer

    David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is Chief Development Officer at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.

    READ MORE ↓

  • Jan Jezek, Ph.D., Chief Scientific Officer

    Jan Jezek has been Chief Scientific Officer of Arecor since 2007 and has led R&D for the proprietary protein stabilisation technologies of the company’s Arestat™ platform and their application to commercial therapeutic products. Jan is responsible for R&D activities, platform development and IP strategy.

    READ MORE ↓

  • Alan E Smith, CBE, FRS, Ph.D., Non-Executive Director

    Alan Smith is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation, Cambridge MA, where he had overall responsibility for the company’s science.

    READ MORE ↓

  • Andrew J M Richards, CBE, Ph.D., Non-Executive Chair

    Andrew Richards has extensive experience from the UK biotechnology sector in drug development, investment, commercial deals and the successful scale-up of companies.

    READ MORE ↓

  • Sarah Howell, Ph.D., Chief Executive Officer and Executive Director

    Sarah Howell has been Chief Executive Officer of Arecor since 2015.

    READ MORE ↓